Table 6.

Disposition of patients with GI AEs in EVOLVE-MS-2 who rolled over into EVOLVE-MS-1

Patients, n (%)	EVOLVE-MS-2 rollovers
	DRF-rollover n = 239	DMF-rollover n = 225
Any GI AE in EVOLVE-MS-2	81 (33.9)	101 (44.9)
Ongoing in EVOLVE-MS-1	26 (10.9)	26 (11.6)
Discontinued treatment in EVOLVE-MS-1	19 (7.9)	30 (13.3)
Discontinued EVOLVE-MS-1 because of GI AE	0	1 (0.4)
Completed treatment in EVOLVE-MS-1	36 (15.1)	45 (20.0)

AE adverse event, DMF dimethyl fumarate, DRF diroximel fumarate, GI gastrointestinal